Kun for helsepersonell

Søk 

Menu

Close

Logg innLogg ut
LegemiddelTerapiområdeUtforsk merUtforsk merMateriellVideo/podkastNyhetsbrevKontakt oss
Om

Menu

Close

EffektEffektdataStudiedesignKlinisk remisjonTidlig symptomatisk responsEndoskopisk forbedringBiologiske/JAKi-undergrupperIsolert proktittSikkerhetBivirkningerHjerte- og øyebivirkningerKom i gangOpplæringsmateriellMateriellVideo
Endoskopisk forbedring

ELEVATE UC 52

ELEVATE UC 12

Tab Number 3

Tab Number 4

Tab Number 5

A greater proportion of patients experienced endoscopic improvement with VELSIPITY vs placebo1

VELSIPITY reduced inflammation in the colon in ELEVATE UC 52, further demonstrating the effectiveness of treatment1

ReferencesEndoscopic improvement was defined as an endoscopy score (ES) ≤1 (excluding friability).1Mucosal healing

VELSIPITY demonstrated mucosal healing in patients living with UC

A greater proportion of patients experienced mucosal healing with VELSIPITY vs placebo in ELEVATE UC 521

 ReferencesMucosal healing was defined as an endoscopy score (ES) ≤1 (excluding friability) with histologic remission (Geboes Index score <2.0, indicating no neutrophils in the epithelial crypts or lamina propria, no increase in eosinophils, and no crypt destruction, erosions, ulcerations, or granulation tissue).1Efficacy in biologic/JAKi subgroupsSee how effective VELSIPITY was in  patients who were biologic/JAKi naive. Biologiske/JAKi-undergrupperLoadingReference:VELSIPITY (etrasimod) Summary of Product Characteristics.
A greater proportion of patients experienced endoscopic improvement with VELSIPITY vs placebo1

VELSIPITY reduced inflammation in the colon in ELEVATE UC 12, further demonstrating the effectiveness of treatment1

ReferencesEndoscopic improvement was defined as an endoscopy score (ES) ≤1 (excluding friability).1Mucosal healing

VELSIPITY demonstrated mucosal healing in patients living with UC

A greater proportion of patients experienced mucosal healing with VELSIPITY vs placebo in ELEVATE UC 121

 ReferencesMucosal healing was defined as an endoscopy score (ES) ≤1 (excluding friability) with histologic remission (Geboes Index score <2.0, indicating no neutrophils in the epithelial crypts or lamina propria, no increase in eosinophils, and no crypt destruction, erosions, ulcerations, or granulation tissue).1Efficacy in biologic/JAKi subgroupsSee how effective VELSIPITY was in  patients who were biologic/JAKi naive. Biologiske/JAKi-undergrupperLoadingReference:VELSIPITY (etrasimod) Summary of Product Characteristics.
Effekt

Preparatomtale

 
PP-V1A-NOR-0013 | Utarbeidet 08.2024

Pfizer AS, Org.nr 915 213 596

Postadresse: Postboks 3, 1324 Lysaker
Besøksadresse: Drammensveien 288, 0283 Oslo

Tlf.: +47 67 52 61 00


PP-BCP-NOR-0001 juni 2023

Copyright © 2023 Pfizer AS. Innholdet er rettighetsbeskyttet.

 




 
Du forlater nå PfizerPro.no
Nettstedet du kommer til er hverken eid eller kontrollert av Pfizer i Norge. Pfizer i Norge er ikke ansvarlig for innholdet på nettstedet du kommer til.
Kun for helsepersonell

Dette nettstedet er kun for helsepersonell.

Jeg bekrefter at jeg er helsepersonell som definert i legemiddelforskriften §13-1.

Ved å velge "nei" vil du komme til Pfizer.no som er åpen for allmenheten.

Ja Nei